Premium
Consistency of quantitation of HCV genotype 4 from egypt across three HCV‐RNA amplification assays
Author(s) -
Sharkawi Fathia Zaky El,
Chudy Michael,
Hanschmann KayMartin,
Kress Julia,
Nübling C. Micha
Publication year - 2008
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.21325
Subject(s) - genotype , nat , virology , biology , hepatitis c virus , nucleic acid test , flaviviridae , hepacivirus , microbiology and biotechnology , virus , medicine , gene , genetics , covid-19 , pathology , computer network , computer science , disease , infectious disease (medical specialty)
Different quantitative assays for HCV‐RNA are available that report test results in International Units (IU)/ml based on the WHO International Standard. Thus, assays have been calibrated with standard material containing HCV genotype 1, so the consistency of quantitation might differ between assays for other HCV genotypes. Three commercial HCV nucleic acid amplification techniques (HCV–NAT) were compared for quantitation consistency of genotype 4 and 1 specimens from an Egyptian blood donor panel (n = 92). Consistency of quantitation between HCV–NATs was higher for genotype 1 than for genotype 4. Most quantitative results reported by the assays were in the same range, but some genotype 4 samples were missed by two of the assays. The Abbott assay showed higher concentrations for genotype 4 than the two Roche assays. Follow‐up investigations of individuals should use the same assay unless another assay has been validated properly. Standardization of HCV–NAT assays remains an issue. J. Med. Virol. 80:2086–2091, 2008. © 2008 Wiley‐Liss, Inc.